Mar 02, 2023 4:01pm EST Veru Provides FDA Update on Request for Emergency Use Authorization for Sabizabulin for Hospitalized COVID-19 Patients at High Risk for ARDS
Jan 26, 2023 8:30am EST Veru to Report Fiscal 2023 First Quarter Financial Results on February 9, 2023
Jan 10, 2023 8:30am EST Veru Announces Appointment of Dr. David D. Ho as Chairman of its Infectious Disease Scientific Advisory Board
Nov 28, 2022 8:30am EST Veru to Report Fiscal 2022 Fourth Quarter and Full Year Financial Results on December 5, 2022
Nov 09, 2022 8:55pm EST Veru Provides Update on FDA Advisory Committee Meeting Regarding Emergency Use Authorization of Sabizabulin to Treat Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome
Oct 24, 2022 8:30am EDT Veru Announces Late-Breaker Oral Presentation of Sabizabulin Treatment for Hospitalized Adults with COVID-19 on Supplemental Oxygen at Infectious Disease Week 2022
Oct 13, 2022 8:30am EDT Veru to Present Late-Breaker Oral Presentation of Sabizabulin Treatment for Hospitalized Adults with COVID-19 on Supplemental Oxygen at Infectious Disease Week 2022
